Company: NDRA
Filing Date: 2025-04-07
Form Type: 10-K/A
Source: 0001654954-25-003937
Chunk: 20

Company: ENDRA Life Sciences Inc.
Filing Date: 2025-04-07
Form: 10-K/A
Chunk 20
---
 cashless exercise of the Series B Warrant using $ (after adjustment) as the exercise price for that purpose and (y) 3.0.

In connection with the Offering, the Company also issued placement agent warrants (“Placement Agent Warrants” and, together with the pre-funded warrants and the Series Warrants, the “Warrants”) to purchase up to shares of common stock. The purchase price of each share of common stock and accompanying Series Warrants was $ and the purchase price of each pre-funded warrant and accompanying Series Warrants was $.

Warrant Exercises

On May 2, 2023, the Company conducted a registered offering in which the Company issued warrants to purchase shares of common stock for an exercise price per share equal to $. The warrants expire . In December 2023, the Board approved a temporary reduction of the exercise price per share from $ to $. The Company also issued to the underwriter and its designees warrants exercisable for an aggregate of shares of common stock for an exercise price per share equal to $. The warrants expire . During the year ended December 31, 2024, the Company issued a total of shares of its common stock upon warrant exercises for aggregate net proceeds of $.

| F-12 |

Between June 4, 2024 and June 7, 2024, pre-funded warrants were exercised. The company issued a total of shares of its common stock upon the cash exercises of pre-funded warrants and cashless exercises of pre-funded warrants for aggregate net proceeds of $ (includes net proceeds from sale and exercise of pre-funded warrants). The remaining pre-funded warrants were used to satisfy the exercise price under the warrants’ cashless exercise provision.

Between August 19, 2024 and December 31, 2024, the Company issued a total of shares of its common stock upon the alternate cashless exercise of Series B Warrants.

The following table summarizes all stock warrant activity of the Company for the year ended December 31, 2024:

|                                          |     | Number of Warrants |          |   |     | Weighted AverageExercise Price |          |     | Weighted Average Contractual Term (Years) |      |
|:-----------------------------------------|:----|:-------------------|---------:|:--|:----|:-------------------------------|---------:|:----|:------------------------------------------|-----:|
| Balance outstanding at December 31, 2023 |     |                    |      493 |   |     | $                              | 2,758.